{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:14:41Z","timestamp":1792419281513,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.comppsych.2024.152479","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T19:24:05Z","timestamp":1711308245000},"page":"152479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Meta-analysis of the comparative efficacy of benzodiazepines and antidepressants for psychic versus somatic symptoms of generalized anxiety disorder"],"prefix":"10.1016","volume":"132","author":[{"given":"Chad","family":"Beyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Currin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.comppsych.2024.152479_bb0075","doi-asserted-by":"crossref","DOI":"10.7326\/AITC201904020","article-title":"Generalized anxiety disorder","volume":"170","author":"Demartini","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.comppsych.2024.152479_bb0200","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamapsychiatry.2017.0056","article-title":"Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe","volume":"74","author":"Ruscio","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.comppsych.2024.152479_bb0235","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4088\/JCP.s.7002.01","article-title":"Overview of generalized anxiety disorder: epidemiology, presentation, and course","volume":"70","author":"Weisberg","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0240","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/da.10065","article-title":"Generalized anxiety disorder: prevalence, burden, and cost to society","volume":"16","author":"Wittchen","year":"2002","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.comppsych.2024.152479_bb0095","article-title":"Pharmacotherapy of anxiety disorders: current and emerging treatment options","volume":"11","author":"Garakani","year":"2020","journal-title":"Front Psychol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0210","article-title":"An examination of factor structure of the Hamilton anxiety rating scale in a non-clinical Persian sample","volume":"10","author":"Slater","year":"2019","journal-title":"Int J Res Nurs"},{"key":"10.1016\/j.comppsych.2024.152479_bb0245","first-page":"153","article-title":"Duloxetine in the treatment of generalized anxiety disorder","volume":"2","author":"Wright","year":"2009","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.comppsych.2024.152479_bb0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00004850-199300830-00006","article-title":"A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder","volume":"8","author":"Boyer","year":"1993","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0120","first-page":"293","article-title":"Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms","volume":"49","author":"Hoehn-Saric","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0175","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","article-title":"Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam","volume":"62","author":"Rickels","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1755-5949.2008.00075.x","article-title":"Clinical evaluation of the daily assessment of symptoms-anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder","volume":"15","author":"Feltner","year":"2009","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.comppsych.2024.152479_bb0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004714-200102000-00011","article-title":"Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group","volume":"21","author":"Moller","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0160","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0005","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1176\/appi.ajp.161.9.1642","article-title":"Efficacy of sertraline in a 12-week trial for generalized anxiety disorder","volume":"161","author":"Allgulander","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S1461145709990423","article-title":"Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study","volume":"13","author":"Bandelow","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0065","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1600-0447.2005.00529.x","article-title":"Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors","volume":"111","author":"Dahl","year":"2005","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.comppsych.2024.152479_bb0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","article-title":"Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study","volume":"19","author":"Davidson","year":"2004","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.comppsych.2024.152479_bb0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/YIC.0000000000000096","article-title":"Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study","volume":"30","author":"Gommoll","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/YIC.0b013e32807fb1b2","article-title":"Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial","volume":"22","author":"Hartford","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0125","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1017\/S1461145714000017","article-title":"Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine","volume":"17","author":"Kasper","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0180","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","article-title":"Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder","volume":"157","author":"Rickels","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0205","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/da.20271","article-title":"Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial","volume":"25","author":"Rynn","year":"2008","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.comppsych.2024.152479_bb0010","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1185\/030079907X182202","article-title":"Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials","volume":"23","author":"Allgulander","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.comppsych.2024.152479_bb0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/da.20695","article-title":"Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder","volume":"27","author":"Coric","year":"2010","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.comppsych.2024.152479_bb0080","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4088\/JCP.15m09885","article-title":"Efficacy and safety of Vilazodone in patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled, flexible-dose trial","volume":"77","author":"Durgam","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000118565","article-title":"Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone","volume":"21","author":"Feighner","year":"1989","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.comppsych.2024.152479_bb0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/da.22365","article-title":"A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder","volume":"32","author":"Gommoll","year":"2015","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.comppsych.2024.152479_bb0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/YIC.0b013e32834d9f49","article-title":"Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study","volume":"27","author":"Merideth","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S0033291708003401","article-title":"Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial","volume":"39","author":"Nicolini","year":"2009","journal-title":"Psychol Med"},{"key":"10.1016\/j.comppsych.2024.152479_bb0220","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study","volume":"75","author":"Stein","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0015","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/0004867418799453","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder","volume":"52","author":"Andrews","year":"2018","journal-title":"Austral New Zealand J Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision","volume":"9","author":"Bandelow","year":"2008","journal-title":"World J Biol Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.comppsych.2024.152479_bb0140","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0215","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.comppsych.2024.152479_bb0035","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0055","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1185\/03007998909115213","article-title":"A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety","volume":"11","author":"Cohn","year":"1989","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.comppsych.2024.152479_bb0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/YIC.0b013e32831d7980","article-title":"Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial","volume":"24","author":"Kasper","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2024.152479_bb0250","first-page":"3260","article-title":"Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China","volume":"124","author":"Wu","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.comppsych.2024.152479_bb0170","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1993.01820230054005","article-title":"Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam","volume":"50","author":"Rickels","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0185","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/archpsyc.1988.01800290060008","article-title":"Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone","volume":"45","author":"Rickels","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1532-5415.2002.50003.x","article-title":"Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials","volume":"50","author":"Katz","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.comppsych.2024.152479_bb0190","first-page":"81","article-title":"Buspirone and diazepam in anxiety: a controlled study","volume":"43","author":"Rickels","year":"1982","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0195","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.160.4.749","article-title":"Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study","volume":"160","author":"Rickels","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2024.152479_bb0225","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/wps.20919","article-title":"The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management","volume":"20","author":"Stein","year":"2021","journal-title":"World Psychiatry"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X24000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X24000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T20:51:19Z","timestamp":1715115079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X24000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":46,"alternative-id":["S0010440X24000300"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2024.152479","relation":{},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis of the comparative efficacy of benzodiazepines and antidepressants for psychic versus somatic symptoms of generalized anxiety disorder","name":"articletitle","label":"Article Title"},{"value":"Comprehensive Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.comppsych.2024.152479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152479"}}